Send us Fan Mail
Nearly a decade after the last major cholesterol guidelines were released, the new 2026 Multi-Specialty Lipid Guidelines introduce significant changes in how cardiovascular risk is assessed and managed. In this episode, Albert Lopez, DO, FACP, FASPC, explains why LDL cholesterol treatment goals have returned, how newer markers such as ApoB and Lipoprotein(a) are reshaping risk assessment, and why earlier, more aggressive treatment may help reduce the world's leading cause of death, cardiovascular disease.
Dr. Al Lopez, DO, discusses the role of statins, non-HDL cholesterol, triglycerides, genetic cholesterol disorders, screening recommendations for children and older adults, and the importance of a team-based approach to prevention. Whether you're a healthcare professional or someone interested in protecting your heart health, this episode provides a practical overview of the latest evidence-based recommendations for preventing heart disease.
Be a part of advancing science by participating in clinical research.
Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.com
Listen on Spotify
Listen on Apple Podcasts
Watch on YouTube
Share with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.
Follow us on Social Media:
Facebook
Instagram
X (Formerly Twitter)
LinkedIn
Want to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.com
Music: Storyblocks - Corporate Inspired
Thank you for listening!